期刊論文
學年 | 96 |
---|---|
學期 | 1 |
出版(發表)日期 | 2008-01-01 |
作品名稱 | Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study |
作品名稱(其他語言) | |
著者 | Lane, Hsien-Yuan; Liu, Yi-Ching; Huang, Chieh-Liang; Chang, Yue-Cune; Liau, Chun-Hui; Perng, Cheng-Hwang; Tsai, Guochuan E. |
單位 | 淡江大學數學學系 |
出版者 | Philadelphia: Elsevier Inc. |
著錄名稱、卷期、頁數 | Biological Psychiatry 63(1), pp.9–12 |
摘要 | Background Small molecules that enhance the N-methyl-D-aspartate (NMDA) neurotransmission have been shown to be beneficial as adjuvant therapy for schizophrenia. Among these compounds, sarcosine (a glycine transporter-I inhibitor), when added to an existing regimen of antipsychotic drugs, has shown its efficacy for both chronically stable and acutely ill patients. However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated. Methods Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily. Results Overall, patients in the 2-g group were more likely to respond as defined by a 20% or more reduction of the Positive and Negative Syndrome Scale total score, particularly among antipsychotic-naïve patients. However, there was no significant between-group difference in the sarcosine dose × time interaction analysis. Both doses were well tolerated with minimal side effects. Conclusions Although patients receiving the 2-g daily dose were more likely to respond, it requires further clarification whether the effect is limited to the antipsychotic-naive population. Future placebo- or active-controlled, larger-sized studies are needed to fully assess sarcosine’s effects. |
關鍵字 | Glutamate; GlyT-1; N-methyl-D-aspartate; sarcosine; schizophrenia |
語言 | en |
ISSN | 0006-3223 |
期刊性質 | 國外 |
收錄於 | SCI |
產學合作 | |
通訊作者 | Tsai, Guochuan E. |
審稿制度 | 是 |
國別 | USA |
公開徵稿 | |
出版型式 | 紙本 |
相關連結 |
機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/58785 ) |